Nurix Therapeutics price target lowered to $35 from $36 at Stifel

Stifel lowered the firm’s price target on Nurix Therapeutics (NRIX) to $35 from $36 and keeps a Buy rating on the shares. The firm continues to view Nurix as “a high-quality company” featuring a lead asset, bexobrutideg, with “a clear path to registration in an established multi-billion-dollar CLL market.” The disclosure of incremental bexobrutideg data updates and registrational trial design plans should improve visibility into this path forward, the analyst tells investors.